Wiegratz I, Jung-Hoffmann C, Kuhl H
Department of Obstetrics and Gynecology, J.W. Goethe University Frankfurt, Germany.
Contraception. 1995 Jun;51(6):341-6. doi: 10.1016/0010-7824(95)00098-u.
The effect of a triphasic oral contraceptive containing ethinylestradiol and gestodene (EE/GSD) on various serum hormonal parameters was compared with that of a monophasic formulation containing 35 micrograms ethinylestradiol and 250 micrograms norgestimate (EE/NGM). Blood samples were collected from 46 women on days 2, 11, and 21 of the preceding control cycle and of the third, sixth and twelfth treatment cycle. There was no significant difference in the influence on any hormonal parameter between both formulations. Both EE/GSD and EE/NGM caused a time-dependent suppression of serum dehydroepiandrosterone sulphate (DHEA-S) by 20-30% (p < 0.01) and a reduction of 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide by 50-60% (p < 0.01) during each treatment cycle, while androstenedione levels were reduced by 25% (p < 0.01). There was also a significant decrease in the levels of total testosterone by 30-35% (p < 0.01) and free testosterone by 60% (p < 0.01), while sex hormone-binding globulin (SHBG) was increased by 200-240% on days 11 and 21 (p < 0.01). During the pill-free interval the SHBG levels were reduced to a certain degree but remained elevated by 100% as compared to the pretreatment values. The serum levels of corticosteroid-binding globulin (CBG) which is known to be influenced only by the estrogenic component of combination pills, increased significantly by 170% (p < 0.01) during each treatment cycle. During the pill-free interval of 7 days, the CBG levels decreased but were still elevated by 90-100% as compared to the control cycle. Similarly, the serum levels of cortisol were significantly elevated by 110-140% (p < 0.01) during treatment with both preparations. The results demonstrate a profound suppression of androgen levels and peripheral androgen metabolism.
将含有炔雌醇和孕二烯酮(EE/GSD)的三相口服避孕药与含有35微克炔雌醇和250微克诺孕酯(EE/NGM)的单相制剂对各种血清激素参数的影响进行了比较。在之前的对照周期以及第三个、第六个和第十二个治疗周期的第2天、第11天和第21天,从46名女性身上采集血样。两种制剂对任何激素参数的影响均无显著差异。在每个治疗周期中,EE/GSD和EE/NGM均使血清硫酸脱氢表雄酮(DHEA-S)呈时间依赖性抑制20%-30%(p<0.01),使5α-雄烷-3α,17β-二醇葡糖苷酸降低50%-60%(p<0.01),而雄烯二酮水平降低25%(p<0.01)。总睾酮水平也显著降低30%-35%(p<0.01),游离睾酮降低60%(p<0.01),而在第11天和第21天,性激素结合球蛋白(SHBG)升高200%-240%(p<0.01)。在无药间隔期,SHBG水平有一定程度降低,但与治疗前值相比仍升高100%。已知仅受复方避孕药雌激素成分影响的皮质类固醇结合球蛋白(CBG)血清水平,在每个治疗周期中显著升高170%(p<0.01)。在7天的无药间隔期,CBG水平下降,但与对照周期相比仍升高90%-100%。同样,两种制剂治疗期间,血清皮质醇水平均显著升高110%-140%(p<0.01)。结果表明雄激素水平和外周雄激素代谢受到深度抑制。